



Cidofovir

Updated: October 10, 2017.

OVERVIEW

Introduction

Cidofovir is a nucleoside analogue and antiviral agent which is used in therapy of serious cytomegalovirus infections in immunocompromised patients. Cidofovir has been associated with mild-to-moderate serum aminotransferase elevations during intravenous therapy, but has not been convincingly linked to cases of clinically apparent acute liver injury.

Background

Cidofovir (syə dof' oh vir) is an acyclic nucleoside monophosphate and cytosine analogue with potent activity against replication of several herpes viruses, including cytomegalovirus (CMV). Cidofovir is phosphorylated intracellularly and competes with cytosine, resulting in DNA chain termination and inhibition of DNA viral synthesis. Cidofovir has activity in cell culture against several herpes viruses, papilloma, polyoma, pox and adenoviruses. Cidofovir is poorly absorbed orally and must be given intravenously, usually administered with probenecid to inhibit its rapid renal excretion. Cidofovir is indicated for therapy of cytomegalovirus retinitis and off label is used to treat serious adenovirus and acyclovir-resistant herpes simplex infections in immunocompromised individuals. Cidofovir was approved for use in the United States in 1996 and has limited use, largely because of its potential for nephrotoxicity. Cidofovir is available as an intravenous formulation of 75 mg/mL under the brand name of Vistide. The usually recommended dose in adults is 5 mg/kg infused over one hour, once weekly for two weeks, but dose modifications are required if there is renal insufficiency. Probenecid is given concurrently. Side effects include headache, dizziness, confusion, fever, fatigue, abdominal pain, renal dysfunction and rash.

Hepatotoxicity

Intravenous cidofovir therapy is associated with mild-to-moderate elevations in serum ALT levels in a proportion of patients, but the elevations are usually self-limited and do not require dose modification. Nephrotoxicity is often dose limiting, which may account for the absence of clinically significant cases of liver injury associated with cidofovir therapy. Cases of clinically apparent liver injury have been reported during cidofovir therapy, but the role of this agent has been difficult to define because most patients who receive cidofovir have severe immunodeficiency and are receiving multiple other agents, some of which are known hepatotoxins. Several instances of acute liver failure, lactic acidosis and fatty liver have been described in patients taking cidofovir, but other nucleoside analogues such as zidovudine, stavudine or didanosine were being taken concurrently.

Likelihood score: E (unlikely cause of clinically apparent liver injury).

Mechanism of Injury

The absence of hepatotoxicity from cidofovir is probably related to the fact that it is rapidly excreted in the urine and binds to the anion transported in the convoluted tubules, leading to its accumulation and renal toxicity.

Outcome and Management

The minor aminotransferase elevations associated with cidofovir therapy are usually self-limited and do not require dose modification or discontinuation of therapy.

Drug Class: [Antiviral Agents](#)

Other Antiviral Agents for Herpes Virus Infections: [Acyclovir](#), [Famciclovir](#), [Foscarnet](#), [Ganciclovir](#), [Letermovir](#), [Valacyclovir](#), [Valganciclovir](#)

PRODUCT INFORMATION

REPRESENTATIVE TRADE NAMES

Cidofovir – Vistide®


DRUG CLASS

Antiviral Agents

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

CHEMICAL FORMULA AND STRUCTURE

DRUG	CAS REGISTRY NUMBER	MOLECULAR FORMULA	STRUCTURE
Cidofovir	113852-37-2	C ₈ H ₁₄ N ₃ O ₆ P	 The chemical structure of Cidofovir is shown. It consists of a pyrimidine ring system with a carbonyl group at the 2-position and a nitrogen atom at the 1-position. A 2-(phosphonoethoxy)ethyl group is attached to the 4-position of the pyrimidine ring. The phosphorus atom is double-bonded to one oxygen and single-bonded to three other oxygens, one of which is part of the ethoxy chain.

ANNOTATED BIBLIOGRAPHY

References updated: 10 October 2017

Núñez M. Herpesviridae treatment. Hepatic toxicity of antiviral agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 512-3. (*Review of hepatotoxicity of antiviral agents mentions that ALT elevations, hepatic necrosis and jaundice were reported in clinical trials using cidofovir*)

).

Acosta EP, Flexner C. Antiviral agents(nonretroviral). In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2013, pp. 1593-1622.

(Textbook of pharmacology and therapeutics).

Lea AP, Bryson HM. Cidofovir. Drugs 1996; 52: 225-30. PubMed PMID: 8841740.

(Review of structure, mechanism of action, pharmacokinetics, efficacy and safety of cidofovir, a cytidine nucleotide analogue shown to be effective in treatment of CMV retinitis; no mention of liver toxicity).

Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Ann Intern Med 1997; 126: 264-74. PubMed PMID: 9036798.

(Randomized controlled trial of low vs high dose cidofovir in 64 patients with small peripheral CMV retinitis and AIDS; complications included neutropenia and proteinuria; no mention of hepatotoxicity or ALT elevations).

Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997; 126: 257-63. PubMed PMID: 9036797.

(Controlled trial of 4 weeks of cidofovir in 48 patients with CMV retinitis and HIV infection; neutropenia [15%] and proteinuria [12%] were the most significant adverse events; no mention of hepatotoxicity or ALT elevations).

Jacobson MA. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 105-15. PubMed PMID: 9211681.

(Review of natural history, outcome and therapy of CMV retinitis focusing on ganciclovir, foscarnet and cidofovir; no mention of hepatotoxicity in discussion of side effects of the 3 drugs).

Lalezari JP. Cidofovir: a new therapy for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14 (Suppl 1): S22-6. PubMed PMID: 9058614.

(Review of safety and efficacy of cidofovir as therapy of CMV retinitis; no mention of hepatotoxicity).

Lalezari JP, Holland GN, Kramer F, McKinley GF, Kemper CA, Ives DV, Nelson R, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 339-44. PubMed PMID: 9525435.

(Controlled trial of two doses of intravenous cidofovir every 1-2 weeks for up to 1 year; no mention of hepatotoxicity or ALT elevations).

Plosker GL, Noble S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs 1999; 58: 325-45. PubMed PMID: 10473024.

(Review of efficacy and safety of cidofovir for CMV retinitis in HIV-infected patients; nephrotoxicity is the major dose limiting adverse effect; no mention of hepatotoxicity or ALT elevations during therapy).

Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Research 2006; 71: 154-63. PubMed PMID: 16765457.

(Review of CMV infection and the drugs used to treat it, including cidofovir, ganciclovir, foscarnet and acyclovir, does not mention ALT elevations or hepatotoxicity).

Drugs for non-HIV viral infections. *Treat Guidel Med Lett* 2007; 5: 59-70. PubMed PMID: 17565338.

(Review of status of non-antiretroviral antiviral agents for prevention and treatment of herpes, varicella-zoster, cytomegalovirus, influenza A and B, and hepatitis B and C; no mention of liver related side effects for cidofovir).

Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. *Gastroenterology* 2008; 135: 1924-34. PubMed PMID: 18955056.

(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, 8 were attributed to antiviral agents including one due to valacyclovir, but none were attributed to cidofovir).

Caruso Brown AE, Cohen MN, Tong S, Braverman RS, Rooney JF, Giller R, Levin MJ. Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients. *Antimicrob Agents Chemother* 2015; 59: 3718-25. PubMed PMID: 25733509.

(Among 12 children with various symptomatic and severe herpes or adenoviral infections after hematopoietic cell transplantation who were treated with a single dose of cidofovir, there were no instances of hepatotoxicity, but two children developed renal dysfunction).

Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. *Gastroenterology* 2015; 148: 1340-52.e7. PubMed PMID: 25754159.

(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 12 cases were attributed to antiviral agents, but none to cidofovir).